Table 2 Lesion characteristics and treatment parameters
Parameter | Number of lesions absolute relative | |
|---|---|---|
Number of lesions with follow up ≥3 months | 52 | 100% |
Location of metastasis | ||
 Left | 26 | 50.0% |
 Right | 25 | 48.1% |
 Midline | 1 | 1.9% |
 Frontal | 19 | 36.5% |
 Parietal | 6 | 11.5% |
 Temporal | 8 | 15.4% |
 Occipital | 6 | 11.5% |
 Frontotemporal | 1 | 1.9% |
 Temporoparietal | 1 | 1.9% |
 Parietooccipital | 1 | 1.9% |
 Cerebellum | 3 | 5.8% |
 Others (basal ganglia, insular cortex, parahippocampal, parafalcin) | 7 | 13.5% |
GTV to PTV margin (mm) | ||
 2 mm | 24 | 46.2% |
 3 mm | 28 | 53.8% |
Prescribed dose (Gy) | ||
 15 | 1 | 1.9% |
 17 | 2 | 3.8% |
 18 | 17 | 32.7% |
 20 | 30 | 57.7% |
 24 | 2 | 3.8% |
Prescribed isodose (%) | ||
 70 | 1 | 1.9% |
 80 | 51 | 98.1% |
Treatment planning software | ||
 Oncentra Masterplan | 30 | 57.7% |
 Monaco | 17 | 32.7% |
 Radionics | 5 | 9.6% |
Fixation technique | ||
 Frameless Brainlab mask | 9 | 17.3% |
 Frameless double thermoplastic mask | 38 | 73.1% |
 Invasive fixed head frame | 5 | 9.6% |
Targeted/ immunotherapy (TT/IT) | ||
 BRAFi | 5 | 9.6% |
 MEKi | 1 | 1.9% |
 Anti-CTLA-4 | 4 | 7.7% |
 Anti-PD1 | 14 | 26.9% |
 BRAFi+MEKi | 6 | 11.5% |
 Anti-PD1 + Anti-CTLA-4 | 10 | 19.2% |
 Triple combination | 2 | 3.8% |
 none | 10 | 19.2% |
Application of TT/IT | ||
 Before SRS (median: 9.5 days, range: 3-43 days) | 24 | 46.2% |
 Concurrent before SRS (median: 8 days, range: 3–21 days) | 21 | 40.4% |
 After SRS (median: 9 days, range: 2–97 days) | 39 | 75.0% |
 Concurrent after SRS (median: 8 days, range: 2–27 days) | 15 | 28.8% |
 Concurrent (4 weeks before or 4 weeks after SRS) | 36 | 69.2% |